Iovance begins Phase II trial of LN-145 for cervical cancer

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) began the Phase II C-145-04 trial of LN-145 to treat cervical cancer. The open-label, U.S. trial will enroll up to 47 patients with recurrent, metastatic or persistent cervical cancer.

The primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), complete response rate, disease control rate (DCR), duration of response and safety. Initial data are expected in 2018...